Lab Groups’ LDT Comments Will Highlight Barriers To Test Accessibility
This article was originally published in The Gray Sheet
Executive Summary
Laboratory groups, who are facing the prospect of a new regulatory scheme in FDA’s proposed lab-developed test framework, intend to discuss barriers to test accessibility and clinical validation of LDTs in future comments.
You may also be interested in...
Molecular Pathologists Propose Third-Party Review Of High-Risk Dx In Alternative To FDA LDT Plan
The Association for Molecular Pathology wants a Senate panel to consider a legislative alternative to FDA’s proposed lab developed test (LDT) framework, a plan to modernize the Clinical Laboratory Improvement Amendments Act and let CMS or a third party assess high-risk LDT procedures for clinical validity.
Will Lab-Developed Test Makers Be Subject To Device Tax? It Depends, Shuren Suggests At Hearing
Lawmakers at a Sept. 9 House Energy and Commerce Subcommittee raised questions on whether FDA’s plans to regulate lab developed tests will also make labs subject to the device excise tax.
FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions
FDA said its new plan, which can’t be released as a formal draft guidance for another 60 days, would establish a more level playing field between test-kit makers and labs, while being flexible when there is not an FDA-approved alternative to an lab-developed test.